Literature DB >> 1358068

P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site.

D R Ferry1, M A Russell, M H Cullen.   

Abstract

[3H]Vinblastine bound with high affinity to surface membranes prepared from H69/LX4 cells which express P-glycoprotein (P-gp) and as a consequence are multidrug resistant (MDR). The KD was 9.8 +/- 1.5 nM and density of sites 31.2 +/- 8.6 pmol/mg of protein. [3H]Vinblastine binding was inhibited by cytotoxics and agents known to reverse MDR. 1,4-Dihydropyridine MDR reversing agents including nicardipine and nifedipine accelerated the dissociation of [3H]vinblastine from P-gp indicating a negative heterotropic allosteric effect. Cyclosporin A, vincristine and actinomycin D did not alter [3H]vinblastine dissociation kinetics. It is concluded that P-gp possesses at least two allosterically coupled drug acceptor sites, receptor site-1 that is selective for vinca alkaloids and cyclosporin A, and receptor site-2 that is selective for 1,4-dihydropyridines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358068     DOI: 10.1016/0006-291x(92)92404-l

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism.

Authors:  H W van Veen; A Margolles; M Müller; C F Higgins; W N Konings
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 2.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  Quantitative structure-activity relationship and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators.

Authors:  Xiao-Fei Zhou; Qingxiang Shao; Robert A Coburn; Marilyn E Morris
Journal:  Pharm Res       Date:  2005-09-20       Impact factor: 4.200

Review 4.  Molecular basis of drug interaction with L-type Ca2+ channels.

Authors:  J Mitterdorfer; M Grabner; R L Kraus; S Hering; H Prinz; H Glossmann; J Striessnig
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

5.  Multidrug resistance in cancer.

Authors:  D R Ferry; D J Kerr
Journal:  BMJ       Date:  1994-01-15

6.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein.

Authors:  A M Taylor; J Storm; L Soceneantu; K J Linton; M Gabriel; C Martin; J Woodhouse; E Blott; C F Higgins; R Callaghan
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

8.  Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1.

Authors:  Emily Crowley; Megan L O'Mara; Catherine Reynolds; D Peter Tieleman; Janet Storm; Ian D Kerr; Richard Callaghan
Journal:  Biochemistry       Date:  2009-07-07       Impact factor: 3.162

9.  P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.

Authors:  X Declèves; O Chappey; B Boval; E Niel; J M Scherrmann
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 10.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

Authors:  Ahmad R Safa
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.